Canada - English - Health Canada

teva canada limited - voriconazole - tablet - 50mg - voriconazole 50mg - azoles

Canada - English - Health Canada

teva canada limited - voriconazole - tablet - 200mg - voriconazole 200mg - azoles

Canada - English - Health Canada

auro pharma inc - voriconazole - tablet - 50mg - voriconazole 50mg - azoles

Canada - English - Health Canada

auro pharma inc - voriconazole - tablet - 200mg - voriconazole 200mg - azoles

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - voriconazole - film coated tablet - 50 milligram - triazole derivatives

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - voriconazole - film coated tablet - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - it is indicated in adults and children aged 2 years and above as follows: - treatment of invasive aspergillosis. - treatment of candidemia in non-neutropenic patients. - treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). - treatment of serious fungal infections caused by scedosporium spp. and fusarium spp

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - voriconazole - film coated tablet - 50 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - it is indicated in adults and children aged 2 years and above as follows: - treatment of invasive aspergillosis. - treatment of candidemia in non-neutropenic patients. - treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). - treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.

Ireland - English - HPRA (Health Products Regulatory Authority)

xellia pharmaceuticals aps - voriconazole - powder for solution for infusion - 200 milligram(s) - triazole derivatives; voriconazole

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; lactose monohydrate; colloidal anhydrous silica; croscarmellose sodium; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; macrogol 4000 - voriconazole is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; pregelatinised maize starch; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; titanium dioxide; hypromellose; macrogol 4000 - voriconazole is indicated for treatment of the following fungal infections:,invasive aspergillosis.,serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,serious fungal infections caused by scedosporium spp and fusarium spp.,other serious fungal infections, in patients intolerant of, or refractory to, other therapy.,prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.